Browse the corpus

Hyperammonemia is a metabolic disorder characterized by elevated plasma ammonia, a neurotoxin capable of causing encephalopathy, cerebral edema, and life-threatening herniation. Clinical manifestations vary widely, ranging from subtle neurocognitive deficits to seizures, coma, and rapid neurologic decline. Causes include both increased ammonia production and impaired clearance. Pediatric cases often arise from genetic and non-genetic inborn errors of metabolism, while acquired causes include hepatic dysfunction, malignancy, infections, and medication-related toxicity. Impairment of either hepatic or renal clearance can precipitate hyperammonemia. Because early clinical signs are nonspecific, diagnostic delays are common, and specimen handling during ammonia measurement is critical to accuracy. Prompt recognition and urgent intervention with anti-catabolic support, ammonia-lowering agents, renal replacement therapy, or targeted hepatic encephalopathy treatment are essential to minimize morbidity and mortality. Participants in this activity learn to recognize both congenital and acquired causes of hyperammonemia, apply diagnostic algorithms sensitive to patient age and clinical context, and implement evidence-based management strategies. Instruction emphasizes urgent stabilization, appropriate use of nitrogen-scavenging agents, and individualized nutritional interventions, including evidence-supported protein intake in cirrhosis. Learners strengthen competence in selecting dialysis techniques for refractory cases and coordinating care with subspecialists. Collaboration among clinicians, nurses, pharmacists, dietitians, nephrologists, and hepatologists ensures timely intervention, improves diagnostic precision, and optimizes long-term outcomes. An interprofessional team approach reduces complications, supports comprehensive patient education, and enhances quality of care across acute and chronic hyperammonemia settings. Objectives: Compare acute versus chronic presentations of hyperammonemia to guide the urgency of intervention and long-term care strategies. Evaluate clinical presentations across age groups and recognize red-flag features requiring emergent intervention. Implement evidence-based management strategies, including anti-catabolic caloric support, ammonia-lowering agents, and timely initiation of intermittent hemodialysis or continuous renal replacement therapy.

Compare acute versus chronic presentations of hyperammonemia to guide the urgency of intervention and long-term care strategies. Evaluate clinical presentations across age groups and recognize red-flag features requiring emergent intervention. Implement evidence-based management strategies, including anti-catabolic caloric support, ammonia-lowering agents, and timely initiation of intermittent hemodialysis or continuous renal replacement therapy. Communicate the importance of interprofessional coordination in improving time-to-therapy, reducing complications, and optimizing patient outcomes. Access free multiple choice questions on this topic.

Hyperammonemia is a life-threatening metabolic disturbance characterized by elevated plasma ammonia, a neurotoxic nitrogenous compound. Ammonia is primarily generated from intestinal bacterial metabolism and amino acid catabolism, enters the portal circulation, and is normally detoxified in the liver via the urea cycle.[1] Impairment of this pathway due to urea cycle disorders, hepatocellular dysfunction, or portosystemic shunting results in systemic accumulation and neuronal injury.[2] Normal plasma ammonia levels vary with age, being highest in neonates. Clinically, hyperammonemia is defined as more than 100 μmol/L in neonates and more than 50 μmol/L in older children and adults.[2] Concentrations exceeding these thresholds rapidly disrupt cerebral energy metabolism and osmoregulation, leading to encephalopathy, cerebral edema, seizures, coma, and potentially death. In adults, approximately 90% of cases are related to advanced liver disease, most commonly cirrhosis or acute liver failure.[1][2] Nonhepatic causes include urea cycle disorders and other inborn errors of metabolism, infections with urease-producing bacteria, medication-induced hyperammonemia (eg, valproate, select chemotherapeutics), and catabolic stressors such as gastrointestinal bleeding, starvation, surgery, or trauma.[1][3] Because neurologic injury can progress within hours, early recognition and immediate intervention are critical. Initial management focuses on rapid ammonia reduction and suppression of catabolism while the underlying precipitant is identified and addressed.[1] Optimal care requires coordinated involvement of hepatology, medical genetics and metabolism, neurology, nephrology, and nutrition.[1]

Hyperammonemia results from impaired hepatic detoxification or excess ammonia production. Causes are congenital (inborn errors of metabolism) or acquired (hepatic and non-hepatic). Early mechanism identification guides emergent therapy and long-term management (see Image. Hyperammonemia, Laboratory Diagnosis Table). Pediatric Causes Congenital causes (inborn errors of metabolism) Urea cycle disorders: Pathogenic variants in NAGS, CPS1, OTC, ASS1, ASL, or ARG1 reduce urea formation. Inheritance is autosomal recessive, except for ornithine transcarbamylase (OTC), which is X-linked.[4][5][6] Proximal defects (NAGS/CPS1/OTC): Classically present at 24 to 48 hours with lethargy, vomiting, seizures, and encephalopathy [7][8] Arginase (ARG1) deficiency: Typically milder hyperammonemia; signs are spasticity from hyperargininemia [9][10] Transient hyperammonemia of the newborn (THAN): Predominantly in preterm infants due to immature urea-cycle function and hepatic hypoxia/microthrombosis; onset at 24 to 48 hours Mimics urea cycle disorders but often resolves with supportive care (dialysis if severe) [11] Nonurea cycle genetic causes Organic acidemias (propionic, methylmalonic): CPS1 inhibition; often with metabolic acidosis/ketosis Fatty-acid oxidation defects (medium-chain acyl-coenzyme A [CoA] dehydrogenase; late-onset multiple acyl-CoA dehydrogenase deficiency [MADD]): Hyperammonemic encephalopathy possible; some MADD cases are riboflavin-responsive [12] Transporter/mitochondrial disorders: HHH (SLC25A15); lysinuric protein intolerance (SLC7A7); citrin deficiency (adult-onset citrullinemia type II); carbonic anhydrase VA deficiency (may respond to carglumic acid); hyperinsulinism–hyperammonemia (GLUD1 ± SLC25A36) [13][14] Others (rare): Adult-onset 3-methylcrotonyl-CoA carboxylase deficiency; selected mitochondrial DNA depletion syndromes [7] Perinatal causes These causes include severe perinatal asphyxia and neonatal herpes simplex virus with hepatic failure.[15] Reye syndrome Reye syndrome is a rare but serious condition that typically affects children and adolescents recovering from a viral infection, such as influenza or varicella (chickenpox). This condition is often associated with aspirin use during the viral illness, though the exact mechanism isn’t fully understood. Acquired Causes Hepatic causes (hepatic encephalopathy) Type A: Acute liver failure (viral, ischemic, toxins)

Reye syndrome is a rare but serious condition that typically affects children and adolescents recovering from a viral infection, such as influenza or varicella (chickenpox). This condition is often associated with aspirin use during the viral illness, though the exact mechanism isn’t fully understood. Acquired Causes Hepatic causes (hepatic encephalopathy) Type A: Acute liver failure (viral, ischemic, toxins) Type B: Portosystemic shunting without intrinsic liver disease (congenital or post-surgical) Type C: Cirrhosis with portal hypertension (eg, hepatitis B and C viruses, Wilson disease, alpha-1 antitrypsin deficiency, cystic fibrosis) Common precipitants: Renal failure, gastrointestinal bleeding, infection, and dehydration [1][16] Nonhepatic causes Hematologic malignancy/therapy: Acute lymphocytic leukemia; myeloma; asparaginase commonly causes transient hyperammonemia; severe cases require intensive care unit care and ammonia-lowering therapy. Infections, urease producers: Proteus, Klebsiella, Morganella, Providencia, Staphylococcus saprophyticus (often with urinary obstruction/retention) Corynebacterium urealyticum (encrusted pyelitis, post-transplant) Ureaplasma (transplant/immunocompromised) may cause fulminant hyperammonemia—treat promptly with targeted antimicrobials plus concurrent ammonia-lowering therapy [17][18] Infections, nonurease mechanisms: Actinotignum schaalii urinary tract infection, severe pneumonia with ammonia-producing airway flora, pleural empyema, and pylephlebitis Management hinges on source control and appropriate antimicrobials.[19][20] Unmasked urea cycle disorders: Partial defects can decompensate with illness, surgery, total parenteral nutrition, pregnancy/postpartum, or after bariatric surgery Drugs/toxins: Valproate (risk increased with topiramate, high dose, liver disease, carnitine deficiency), valproate–topiramate combination, 5-fluorouracil ± platinum; others include carbamazepine, ribavirin, sulfadiazine, salicylates, amiodarone, endoxifen, deferasirox (via Fanconi syndrome), L-asparaginase [3][21] Procedure-related: Operative hysteroscopy with glycine absorption causing hypo-osmolar hyponatremia and hyperammonemia; correct fluid/solute imbalance Systemic states: Renal failure, severe malnutrition, gastrointestinal bleeding, high tumor burden, severe dehydration (transient elevations normalize with rehydration) [1][16]

Procedure-related: Operative hysteroscopy with glycine absorption causing hypo-osmolar hyponatremia and hyperammonemia; correct fluid/solute imbalance Systemic states: Renal failure, severe malnutrition, gastrointestinal bleeding, high tumor burden, severe dehydration (transient elevations normalize with rehydration) [1][16] Transplant recipients: Lung and hematopoietic stem cell transplant recipients are vulnerable to fulminant, often infection-related, hyperammonemia with high morbidity/mortality [22] Adults without liver disease: Consider urease-producing infections, valproate (± topiramate), hematologic malignancy/therapy, and vascular anomalies.[19][23][24][25][26]

Hyperammonemia patterns vary by age and etiology. In adults, most cases stem from advanced liver disease or portosystemic shunting; in neonates/children, inborn errors of metabolism dominate non-hepatic causes.[11][26] Urea cycle disorders: Historical incidence ~1:35,000 live births; contemporary estimates up to ~1:8200 in the United States. Ornithine transcarbamylase, a key enzyme in the urea cycle, responsible for detoxifying ammonia in the liver, is the most common single defect.[5][6][27] Screening: ASS1/ASL defects and several organic acidemias are on standard newborn screens (NBS); ornithine transcarbamylase and N-acetylglutamate synthase are typically not part of NBS; therefore, a normal NBS does not exclude a urea cycle disorder in symptomatic infants.[28] Age/presentation: Early-onset disease presents at 24 to 72 hours with severe hyperammonemia.[29] Partial/late-onset forms may first appear in childhood or adulthood, often triggered by infection, surgery, pregnancy/postpartum, total parenteral nutrition, or post-bariatric states.[30][31]

Hyperammonemia occurs when ammonia production exceeds hepatic detoxification. Portal venous ammonia is normally converted to urea in the liver. Extrahepatic tissues (skeletal muscle, brain, kidney) buffer nitrogen by forming glutamine and alanine, but this sink is quickly overwhelmed during acute or sustained elevations.[32][33][34] See Image. Urea Cycle. Sources of Ammonia (Amino Acid Catabolism) Gut/colon: Bacterial urease and protein metabolism [35] Small intestine: Enterocyte glutaminase (augmented by bacterial overgrowth) Skeletal muscle: Amino-acid transamination and the purine-nucleotide cycle [34] The amino acids that directly produce ammonia are glutamine, glutamate, and asparagine Aspartate, glutamate, glutamine, and the urea cycle amino acids are also especially important [36] Central Nervous System Mechanisms Astrocyte swelling leading to cerebral edema represents the core pathway of hyperammonemic neurotoxicity. Ammonia readily crosses the blood–brain barrier, where astrocytic glutamine synthetase converts ammonia and glutamate into glutamine. Intracellular accumulation of glutamine acts as an osmolyte, driving cytotoxic edema. This cascade results in mitochondrial dysfunction, enhanced oxidative and nitrosative stress, disrupted potassium and water homeostasis, and activation of programmed cell death pathways.[32] Neurotransmitter dysregulation Glutamatergic excitotoxicity arises when excess extracellular glutamate overactivates N-methyl-D-aspartate receptors, increasing sodium–potassium adenosine triphosphatase demand, depleting cellular adenosine triphosphate, and ultimately precipitating seizures and neuronal injury.[37][38] Chronic adaptations: Persistent extrasynaptic glutamate impairs receptor signaling and the glutamate–NO–cyclic guanosine monophosphate pathway, driving cognitive deficits in hepatic encephalopathy.[39] Gamma-aminobutyric acid (GABA) GABAergic tone: Endogenous benzodiazepine-like ligands/neurosteroids enhance inhibition and depress synaptic activity.[40][41] Serotonergic changes: Altered tryptophan transport can raise central serotonin and contribute to anorexia in chronic hyperammonemia.[42] Structural Injury and Biomarkers

Gamma-aminobutyric acid (GABA) GABAergic tone: Endogenous benzodiazepine-like ligands/neurosteroids enhance inhibition and depress synaptic activity.[40][41] Serotonergic changes: Altered tryptophan transport can raise central serotonin and contribute to anorexia in chronic hyperammonemia.[42] Structural Injury and Biomarkers Chronic or recurrent hyperammonemia is linked to characteristic white-matter injury, often involving corticospinal tracts. Advanced neuroimaging (eg, diffusion tensor imaging) can detect microstructural changes and is being explored as a biomarker of disease burden and recovery in uric cycle disorder (UCDs).[43][35] Exposure Dynamics In UCDs, neurotoxicity reflects astrocytic glutamine accumulation, oxidative stress, and impaired neurotransmission. Rapid rises in ammonia correlate more strongly with acute brain injury than cumulative exposure alone.[35] Hepatic and Systemic Effects Ammonia is both neurotoxic and hepatotoxic; it promotes oxidative stress, mitochondrial permeability transition, apoptosis/necroptosis, and fibrogenesis, worsening hepatic dysfunction and perpetuating hyperammonemia.[44][45] Within the gut–liver–brain axis, ammonia drives liver injury and hepatic encephalopathy, not merely a biomarker.[46] Etiology-Specific Notes Asparaginase: Therapeutic asparagine depletion can increase ammonia generation; risk is context dependent.[47] Mitigation aims to preserve anticancer efficacy while limiting toxicity.[48] Research insights: Multi-omics studies demonstrate broad alterations in neurotransmission, oxidative-stress responses, mitochondrial function, and protein-synthesis pathways; hypomorphic CPS1 models show disrupted neuronal maturation/synaptic signaling with long-term neurodevelopmental deficits, mirroring clinical observations.[49]

History The presentation ranges from subtle neurocognitive changes to fulminant encephalopathy, and the age of onset (neonatal, childhood, adult) often reflects the etiology. Neonatal/early-onset Timing: 24 to 72 hours after birth, as nitrogen load rises; ammonia is typically higher than 100 to 150 μmol/L Features: Poor feeding, somnolence, irritability, vomiting, hypothermia, hypotonia Progression: Hyperventilation with respiratory alkalosis, which can lead to apnea, abnormal posturing, seizures, and coma (≈50% of severe cases develop seizures without rapid therapy) [11] Late-onset (childhood/adult) Contexts: Partial UCDs or acquired causes. Precipitants: Infection (eg, gastroenteritis, spontaneous bacterial peritonitis), surgery/trauma, gastrointestinal bleeding, high-protein intake, pregnancy/postpartum, constipation, diuresis, total parenteral nutrition [50] Symptoms: Irritability, headache, vomiting, ataxia, confusion/mood change/psychosis; risk of seizures, cerebral edema, and coma increases when ammonia >200 μmol/L Protein aversion and cyclical unexplained nausea/vomiting may be present.[51] Psychiatric presentations: Consider metabolic evaluation in atypical or refractory cases.[52] Chronic/recurrent hyperammonemia Effects: Intellectual disability, executive dysfunction, learning, and psychiatric disorders Mechanism: Linked to astrocytic glutamine accumulation and neurotransmission abnormalities. Cirrhosis/minimal hepatic encephalopathy: Fluctuating disorientation, poor concentration, sleep–wake inversion. Even mild elevations impair cognition, supporting surveillance and treatment. Physical Examination Findings reflect neurologic, systemic, and hepatic involvement and are often nonspecific. Neurologic Early: Impaired attention, irritability, disorientation, slurred speech Progressive: Asterixis, ataxia, seizures, altered sensorium → stupor/coma Focal deficits: Uncommon in isolated hyperammonemia; prompt evaluation for alternative/additional diagnoses (eg, stroke, central nervous system infection) Clinical correlation: Level of consciousness typically worsens as ammonia rises, especially when greater than 200 μmol/L—though correlation is imperfect.[52] Metabolic clues (inborn errors of metabolism): Isovaleric acidemia (sweaty-feet odor); argininosuccinic aciduria (brittle, fragile hair) Systemic/hepatic

Focal deficits: Uncommon in isolated hyperammonemia; prompt evaluation for alternative/additional diagnoses (eg, stroke, central nervous system infection) Clinical correlation: Level of consciousness typically worsens as ammonia rises, especially when greater than 200 μmol/L—though correlation is imperfect.[52] Metabolic clues (inborn errors of metabolism): Isovaleric acidemia (sweaty-feet odor); argininosuccinic aciduria (brittle, fragile hair) Systemic/hepatic The stigmata of chronic liver disease and portal hypertension include jaundice, hepatomegaly, ascites with shifting dullness, spider angiomata, gynecomastia, pedal edema, and caput medusae. Fetor hepaticus supports the diagnosis of hepatic encephalopathy. Dehydration and tachypnea may accompany recurrent vomiting and respiratory alkalosis.[53] Hepatic Encephalopathy Grading (West Haven) Grade 0 (minimal): Subclinical; psychometric deficits (attention, memory) Grade 1: Sleep–wake reversal, reduced attention, mild disorientation, mood/behavior change Grade 2: Lethargy, apathy, disorientation, slurred speech, personality change, asterixis Grade 3: Somnolent but arousable; marked confusion, gross disorientation Grade 4: Coma with absent/minimal response to pain Pediatric Considerations In children, especially with acute liver failure, hepatic encephalopathy presents variably and carries a higher risk of cerebral edema. Maintain a low threshold for intensive care unit-level monitoring and neuroprotective measures when signs of intracranial hypertension emerge.[51]

Newborn Screening Many disorders (eg, ASS1, ASL, and several organic acidemias) are detected; however, OTC and NAGS are typically not on this screen. A high suspicion despite a normal screen must be maintained.[54][55] Hyperammonemia, higher than 100 μmol/L in neonates and higher than 50 μmol/L in children/adults, is a medical emergency due to the rapid risk of cerebral edema and irreversible injury. Plasma ammonia in unexplained encephalopathy, altered mental status, or seizures should be checked.[56] Preanalytical essentials Free-flowing venous/arterial sample in ammonia-free heparin/ethylenediaminetetraacetic acid should be put on ice immediately. Hemolysis and delays should be avoided. Timing and dialysis/procedures should be documented; pre-dialysis samples should be drawn when possible.[57] Stepwise approach A properly handled specimen should be confirmed and repeated if discordant. Etiology should be classified as hepatic (acute liver failure, cirrhosis, shunts) or nonhepatic (UCDs/other inborn error of metabolism, drugs, urease-producing infections, nutritional/metabolic causes). Initial labs: Comprehensive metabolic panel, liver tests (aspartate aminotransferase/alanine aminotransferase, bilirubin, International Normalized Ratio), arterial blood gas/venous blood gas, glucose, lactate, complete blood count, urinalysis. Infectious work-up as indicated (blood/urine cultures; targeted tests) should be performed. Metabolic testing should be done if non-hepatic causes are likely: plasma amino acids, urine organic acids, acylcarnitine, urinary orotic acid (elevated in OTC; low/normal in proximal defects). Review newborn screening in neonates (note: OTC/NAGS usually not detected). Consider enzyme assays if genetics are inconclusive. Imaging and neurophysiology Brain MRI (edema, chronic injury; UCD patterns), electroencephalogram for seizures/nonconvulsive seizures, and abdominal vascular imaging (Doppler/computed tomography/MRI) for shunts or thrombosis should be performed.[58] Adult-focused considerations Partial/late-onset UCDs, urease-producing infections, medication causes, and nutritional deficits should be screened for.[3] Pitfalls: Normal ammonia does not exclude hepatic encephalopathy. In cirrhosis, ammonia correlates poorly with grade; very high levels still signal risk.[59][60]

Brain MRI (edema, chronic injury; UCD patterns), electroencephalogram for seizures/nonconvulsive seizures, and abdominal vascular imaging (Doppler/computed tomography/MRI) for shunts or thrombosis should be performed.[58] Adult-focused considerations Partial/late-onset UCDs, urease-producing infections, medication causes, and nutritional deficits should be screened for.[3] Pitfalls: Normal ammonia does not exclude hepatic encephalopathy. In cirrhosis, ammonia correlates poorly with grade; very high levels still signal risk.[59][60] Intensive care unit underrecognition: In unexplained encephalopathy, ammonia should be checked; involve nephrology/metabolics early. Post-dialysis samples can mask elevations—pre-dialysis draws are preferred. Seizures (± valproate) can transiently raise ammonia—interpret in context.[61] Risk of hyperammonemia increases with valproate, along with topiramate, carnitine deficiency, liver dysfunction, and high drug levels; improves with withdrawal ± carnitine.[3] Other culprits, such as asparaginase, chemotherapeutics, antibiotics, and psychotropics, should stop early; consider nitrogen scavengers when indicated. Clinical insight Stabilization and ammonia-lowering therapy must begin in parallel with cause identification to prevent irreversible neurologic injury.

Treatment of hyperammonemia is time-critical. Stabilization, rapid ammonia reduction, and etiologic testing must proceed in parallel. Core steps are consistent across causes, with disease-specific modifications (UCDs/inborn error of metabolism (IEMs) vs hepatic failure vs drug/infection-related).[62] Initial stabilization (minutes–hours) Airway, breathing, circulation: Secure airway; maintain hemodynamics; admit to intensive care unit (ICU) for severe encephalopathy or suspected cerebral edema.[62] Immediate protein restriction: Stop all exogenous protein/nitrogen (including total parenteral nutrition). Anti-catabolic calories: Start intravenous (IV) glucose ~8–10 mg/kg/min; add IV lipid as needed to reach ~80–100 kcal/kg/day.[56] Correct derangements: Treat hypoglycemia, acidosis, and electrolyte abnormalities; maintain normothermia/euvolemia; use isotonic fluids for hypotension. Monitoring: Check ammonia every 2–4 h; perform serial neurological exams. Obtain neuroimaging if edema is suspected; consider intracranial pressure monitoring in fulminant hepatic failure (where available).[62] Seizures: Avoid valproate; use levetiracetam or benzodiazepines. Extracorporeal ammonia removal Intermittent hemodialysis (IHD): First-line for severe/refractory hyperammonemia (eg, >300–500 μmol/L, coma, or cerebral edema); clearance superior to PD.[63] Continuous renal replacement therapy (CRRT) (continuous venovenous hemodiafiltration): Preferred in neonates or hemodynamic instability; recommended in acute liver failure (ALF).[62] Peritoneal dialysis: Less efficient; use only if IHD/CRRT unavailable. High-volume plasma exchange: ALF with grade II hepatic encephalopathy or higher may improve transplant-free survival; consider it alongside transplant evaluation.[64] ALF emphasis: Hyperammonemia drives cerebral edema and mortality—prioritize early ICU transfer, close ammonia monitoring, and timely RRT.[62] Pharmacologic ammonia-lowering strategies Nitrogen scavengers IV sodium phenylacetate + sodium benzoate: First-line in acute UCD crises (weight-based loading then maintenance).[56] Chronic therapy: oral sodium phenylbutyrate or glycerol phenylbutyrate (often better tolerated). Severe non-UCD hyperammonemia: IV scavengers may be considered when a metabolic mechanism is suspected.[56] Amino-acid supplementation Citrulline: For proximal defects (CPS1, OTC) Arginine: For most UCDs except arginase deficiency

IV sodium phenylacetate + sodium benzoate: First-line in acute UCD crises (weight-based loading then maintenance).[56] Chronic therapy: oral sodium phenylbutyrate or glycerol phenylbutyrate (often better tolerated). Severe non-UCD hyperammonemia: IV scavengers may be considered when a metabolic mechanism is suspected.[56] Amino-acid supplementation Citrulline: For proximal defects (CPS1, OTC) Arginine: For most UCDs except arginase deficiency Carglumic acid (N-carbamyl-L-glutamate) Indication: NAGS deficiency Off-label rescue: Refractory valproate-associated hyperammonemia and selected CPS1 regulatory defects (evidence largely case-based) Adjuncts L-carnitine: Standard in valproate toxicity; may reduce attack frequency in selected metabolic disorders. L-ornithine–L-aspartate, LOLA: Enhances extrahepatic ammonia disposal; effective in hepatic encephalopathy in meta-analyses, though guideline uptake varies.[65] Hepatic encephalopathy–focused care First-line: Lactulose/lactitol titrated to 2 to 3 soft stools/day.[65] Add-on: rifaximin to reduce recurrence/persistence.[1] Selective adjuncts: If response is inadequate, Neomycin or metronidazole (toxicity limits), probiotics/synbiotics, and LOLA.[1] Precipitant control: Treat gastrointestinal bleeding, infection, dehydration/constipation, renal failure, and drug toxicity.[1] ALF nuance: In ALF, nonabsorbable disaccharides/antibiotics have not shown outcome benefit; prioritize rapid ammonia clearance and definitive therapy. Complications and ICU measures Cerebral edema/intracranial hypertension: Prefer hypertonic saline over mannitol; elevate head; maintain normocapnia and oxygenation. In fulminant hepatic failure, propofol sedation and controlled ventilation are considered.[66] Medication cautions: Avoid valproate; minimize sedatives. Corticosteroids worsen nitrogen balance and are not indicated for hyperammonemia itself. Sepsis: Treat aggressively with early source control and antibiotics in parallel with ammonia-lowering therapy. Nutrition and long-term management Protein strategy: Restrict only during the acute crisis. In chronic liver disease, avoid prolonged restriction; ensure adequate protein to prevent sarcopenia. Limit restriction beyond the acute phase (typically ≤24–48 h) unless guided by metabolic specialists.[1] UCD maintenance: Tailored protein-restricted diet ± specialized formulas; oral scavengers; arginine/citrulline and carnitine as indicated.[56] Definitive therapies:

Protein strategy: Restrict only during the acute crisis. In chronic liver disease, avoid prolonged restriction; ensure adequate protein to prevent sarcopenia. Limit restriction beyond the acute phase (typically ≤24–48 h) unless guided by metabolic specialists.[1] UCD maintenance: Tailored protein-restricted diet ± specialized formulas; oral scavengers; arginine/citrulline and carnitine as indicated.[56] Definitive therapies: Liver transplantation—curative for many UCDs and for advanced liver failure–associated hyperammonemia.[56] Emerging therapies: Gene and messenger ribonucleic acid-based approaches under active investigation. Special populations Very-low-birth-weight neonates: CRRT is feasible/safe for ammonia clearance. Pregnancy (UCD carriers/known UCD): Preconception counseling; peripartum plans; aggressive anti-catabolic protocols; rapid access to scavengers/RRT.[56] Post-transplant/immunocompromised: Lung-transplant hyperammonemia (often ureaplasma/mycoplasma) carries high mortality without rapid recognition—start targeted antibiotics and timely RRT; standardized screening practices vary. Vascular anomalies: Intrahepatic portosystemic shunts; closure or resection can resolve encephalopathy in selected cases. Transplant-related: Post-lung or HSCT hyperammonemia (often ureaplasma); requires rapid antimicrobials plus aggressive ammonia-lowering strategies.[67] Practical pearls Treat ammonia when 200 μmol/L or higher (or ≥3× age-adjusted normal in neonates) as a medical emergency. Start anticatabolic calories and ammonia-lowering therapy immediately—do not wait for the full workup. If levels do not fall within hours on scavengers/support, escalate to RRT.[62] Optimal outcomes require early ICU transfer, tight monitoring, and coordinated interprofessional management (hepatology, genetics, nephrology, neurology, nutrition, critical care).[62]

Hyperammonemia mimics many encephalopathic states. Distinguish true elevation from look-alikes with normal ammonia to avoid treatment delay; evaluate sepsis and metabolic causes in neonates in parallel. In cirrhosis, encephalopathy out of proportion to liver dysfunction warrants a search for precipitants/alternatives.[11][68] Infectious and neurologic mimics Neonates: Sepsis, meningitis, intracranial hemorrhage (ICH), hypoxic-ischemic encephalopathy—obtain ammonia at triage while starting sepsis care.[11] Adults: Meningitis/encephalitis, stroke/ICH, tumors, posterior reversible encephalopathy syndrome, and idiopathic intracranial hypertension.[68][69] True trigger: Urease-producing urinary tract infection (UTI) (eg, C urealyticum) → true hyperammonemia; treat with targeted antibiotics, urinary decompression, and ammonia-lowering therapy.[70] Metabolic disorders with normal ammonia Carbohydrate disorders (hypoglycemia), organic acidemias (acidosis/ketosis), pyruvate/mitochondrial disease (lactic acidosis), and homocystinuria (thromboembolism). Uremia usually shows normal/modest ↑ ammonia. Secondary mimics/comorbidities Post-ictal states, hypoxic–ischemic injury, drug-induced encephalopathy (sedatives/opioids/antiepileptics like valproate may also cause true hyperammonemia), severe sepsis/multiple organ failure, fluoropyrimidines; improve with withdrawal/source control.[71] Radiologic overlap MRI findings (eg, insular/cingulate diffusion restriction) are nonspecific; magnetic resonance spectrography/diffusion tensor imaging may support them but is not diagnostic. Do not miss Reye syndrome, transient hyperammonemia of the newborn, and rare transport/auxiliary defects (hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, lysinuric protein intolerance, citrin deficiency, carbonic anhydrase VA deficiency, hyperinsulinism–hyperammonemia).[11][72][73] Unlike urea cycle disorders, which typically present with hyperammonemia, normal anion gap, and normal glucose, organic acidemias and related metabolic defects are usually characterized by metabolic acidosis with an elevated anion gap, a key distinction in the differential diagnosis.[https://www.ncbi.nlm.nih.gov/books/NBK448090/]

Outcomes depend on etiology, peak ammonia, exposure duration, and speed of intervention. Severe or prolonged elevations lead to cerebral edema, seizures, coma, irreversible injury, and death.[35][62] Urea Cycle Disorders Neonatal-onset: ~35% survival at ~11 years; improving with earlier detection, rapid scavengers, and transplant access. Late-onset: ~87% survival at ~11 years with timely recognition/treatment.[6] Morbidity: Common neurocognitive/psychiatric sequelae; severity correlates with age at first crisis, peak ammonia, and time to therapy.[6] Transplantation: Orthotopic liver transplantation is metabolically curative for many; pediatrics have >85% 10-year survival chance; earlier listing improves neurodevelopment.[74] Hepatic Encephalopathy ALF: Short-term mortality ~50%–70%; hyperammonemia predicts intracranial hypertension and poor survival; urgent transplant evaluation is essential.[62] [62]Cirrhosis: Recurrent hepatic encephaly (HE) marks advanced disease; historical 1- and 3-year survival ~42% and 23%; modern outcomes vary by the model for end-stage liver disease (MELD) and transplant access. Secondary/Drug-Related This is generally favorable if promptly recognized and the trigger removed (eg, stop valproate, treat infection); prognosis reflects timeliness and baseline organ reserve.[75] Poor Prognostic Factors A delay in treatment longer than 24 hours, ammonia levels exceeding 200–300 µmol/L or persistently elevated, the presence of seizures or cerebral edema, coma at presentation, delayed initiation of renal replacement therapy when indicated, and advanced hepatic failure with a high MELD score are critical factors associated with poor outcomes in hyperammonemic conditions such as urea cycle disorders or hepatic encephalopathy.[62][35] Emerging and Post-Transplant Biomarkers (plasma glutamine, magnetic resonance spectroscopy of glutamine and glutamate ratios, diffusion metrics) and earlier use of modern scavengers/RRT/timely transplant may improve outcomes. After a transplant for metabolic disease, survival/metabolic stability improves, though neurodevelopment remains variable; early rehabilitation is important.[43][62][76][62][77]

Hyperammonemia causes acute, life-threatening events and chronic sequelae via direct neurotoxicity, systemic effects of the underlying disease, and treatment-related adverse events. Acute neurologic complications Cerebral edema/intracranial hypertension: Astrocytic glutamine–mediated swelling; rapid progression to herniation without prompt therapy.[62] Seizures/status epilepticus: N-methyl-D-aspartate receptor overactivation and energy failure; exacerbate edema and neurologic decline.[46] Coma: Severe levels more than 200 to 300 μmol/L in adults often necessitate ICU care; more than 350–400 μmol/L frequently associate with irreversible injury.[46] Acute liver failure encephalopathy: Ammonia is a principal driver of asterixis, edema, and progressive coma.[62] Chronic neurologic sequelae Neurocognitive impairment: Developmental/intellectual disability, executive and learning deficits, psychiatric symptoms.[78] Motor deficits: Corticospinal-tract injury (advanced imaging) with spasticity and gait disorder. Behavioral/psychiatric disorders: Prominent in late-onset UCDs and chronic HE.[78] Treatment-related complications Rapid correction: Rare demyelination with abrupt osmolar shifts; prioritize ammonia reduction while avoiding large sodium/osmolar changes. RRT events: Intermittent hemodialysis can cause hypotension, arrhythmias, and disequilibrium; CRRT is better tolerated in instability. Nitrogen scavengers: Gastrointestinal upset, anorexia, electrolyte derangements; IV forms add sodium load (worsen edema/heart failure). Medication pitfalls: Valproate may precipitate/worsen hyperammonemia—risk ↑ with topiramate or hepatic dysfunction. Systemic complications Multiorgan dysfunction: Contributions to hepatic failure, renal impairment, and coagulopathy.[62] Infection susceptibility: Due to hospitalization, malnutrition, and immunosuppression (post-transplant/advanced cirrhosis). Growth/nutrition (pediatrics): Excessive protein restriction risks failure to thrive and developmental delay. Long-term and emerging issues Psychiatric burden/quality of life: Increased depression/anxiety in UCD/HE survivors.[79] Post-transplant: risks of rejection and immunosuppressant toxicity; rare metabolic recurrence.[77][62] Neuroimaging predictors: Diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) (elevated glutamine/glutamate peaks) may aid risk stratification and rehabilitation planning.

Core Team Members and Roles Internists/hospitalists recognize early, initiate stabilization, and coordinate multidisciplinary care. Emergency medicine triage ammonia testing/handling, begin empiric stabilization, activate specialty pathways.[56] Hepatology/gastroenterology manages hepatic encephalopathy and cirrhosis-related hyperammonemia; assesses transplant eligibility.[16] Genetics/metabolic diagnosis IEMs guide targeted therapy (eg, carglumic acid and scavengers) and provide genetic counseling.[16] Neonatology/pediatrics lead neonatal/infant care.[11] Neurology manages seizures; guides neuroimaging/electroencephalogram; assesses neurocognitive outcomes. Critical care oversees ICU care, ICP strategies, ventilatory goals, CRRT/hyperammonemic valproate-induced encephalopathy.[62] Nephrology initiates IHD/CRRT; manages renal complications. Pharmacy optimizes the dosing of scavengers and HE therapies, flags interactions (eg, valproate and corticosteroids), adjusts for hepatic and renal impairment, and builds electronic health record alerts for high-risk agents. Dietetics design nutrition plans balancing protein needs with adequate calories. Nursing front-line monitoring, therapy administration, infection prevention, and caregiver education. Other specialists (surgery/urology/hematology) provide transplant evaluation, urinary interventions, and hematologic issues as needed.

Prevention hinges on patient/caregiver education, early symptom recognition, and etiology-specific plans coordinated by a multidisciplinary team. For UCDs, provide a sick-day plan and an emergency letter (weight-based dosing, ED instructions, key contacts).[56][6] General education Warning signs: Lethargy, confusion, vomiting, gait change, new mood/behavior symptoms.[56] Emergency (UCDs): Seek care at the first symptoms; bring the emergency letter. Adherence: continue Nitrogen scavengers, ammonia-lowering agents, and supplements; in cirrhosis, do not stop lactulose/rifaximin without guidance.[16] Diet and lifestyle Calories: Maintain adequate intake, especially during illness, to blunt catabolism.[56] Protein: UCDs are individualized, specialist-guided restrictions; unless directed, avoid fasting/ketogenic diets. Cirrhosis—no routine restriction; ensure protein to prevent sarcopenia; avoid alcohol; prevent constipation.[16][1] Activity: Moderate exercise; avoid prolonged fasting/overexertion Special populations Children (UCDs): Monitor growth/neurodevelopment; ongoing dietetic support.[6] Women of childbearing potential: Preconception genetics; coordinated perinatal plan; avoid valproate. Families at risk: Offer carrier testing and prenatal/antenatal options. Evidence: UCD pregnancies have high maternal/neonatal risk; intensive preconception and peripartum management is required.[80] Preventing acquired hyperammonemia Medications: Review/avoid ammonia-raising agents (eg, valproate, corticosteroids, ribavirin, select chemotherapies) or monitor closely. Infections: Meticulous line/urinary/wound care to limit urease-producing pathogens.[17][19] Cirrhosis care: Reinforce lactulose/rifaximin adherence, bowel regularity, judicious PPI use, and early reporting of GI bleeding/infection; avoid unsupervised sedatives/opioids.[1][16][81] Multidisciplinary support Dietitians, genetics, and behavioral health. Sick-day plans/rescue kits (UCDs): early carbohydrate loading, ED thresholds, on-call contacts. Key messages Act immediately on early symptoms. Never stop ammonia-lowering therapy without advice. Maintain calories during illness; follow individualized protein targets. Keep an updated medication list and flag ammonia-raising drugs. Reintroduce protein within 24 to 48 h after an acute episode as directed.

Pearls and other important information include the following: Treat immediately: Hyperammonemia is an emergency—start anti-catabolic calories and ammonia-lowering therapy without delay. Check correctly: Proper specimen handling (free-flowing sample, on ice, rapid transport) prevents false results that delay care. Thresholds to act: Very high levels (≈>200 μmol/L adults; ≥3× normal in neonates) or any coma/edema warrant urgent ICU and dialysis planning. Dialysis early: If ammonia does not fall within hours or is over 300–500 μmol/L, escalate to IHD (first-line) or CRRT if it is unstable or neonatal. UCD crisis: Give IV nitrogen scavengers promptly; add citrulline/arginine per defect; consider carglumic acid for suspected N-acetylglutamate synthase (NAGS) deficiency. Hepatic encephalopathy: Titrate lactulose to 2–3 soft stools/day; add rifaximin for recurrence prevention; reintroduce protein within 24 to 48 h. Avoid pitfalls: Avoid using valproate (especially with topiramate); search for urease-producing infections and covert portosystemic shunts. Pre-dialysis sampling: Draw ammonia before hemodialysis; post-dialysis values can mask severity. Nutrition: Restrict protein only during the acute phase; chronic restriction in cirrhosis worsens sarcopenia and outcomes. Disposition: Early transfer to centers with renal replacement therapy and transplant/metabolic expertise improves survival and neurologic recovery. Stat pearls Toxicity increases with both ammonia level and exposure duration, progressing from astrocyte swelling to cerebral edema, seizures, coma, and death; prevention relies on early recognition, rapid ammonia reduction, prompt trigger control, careful therapy titration, and ongoing neurologic surveillance. Check ammonia early in unexplained encephalopathy.[68] Confirm true elevation and treat triggers in parallel with ammonia-lowering therapy. Keep a broad differential in suspected nonhepatic cases (ICU); early scavengers or RRT can be lifesaving. Escalating toxicity: Astrocyte swelling → cerebral edema → seizures/coma; greater than 200 μmol/L (adults) or greater than 1000 μmol/L (neonates) demands urgent lowering.[68]

Hyperammonemia is a metabolic emergency that can rapidly cause cerebral edema, intracranial hypertension, encephalopathy, and irreversible brain injury. Early recognition, rapid ammonia reduction, and seamless interprofessional collaboration are essential to improve survival and long-term neurologic outcomes. Patients with hyperammonemia are at high risk of neurologic damage. Early identification and management of patients with this condition are imperative in reducing morbidity and mortality. The care of patients with hyperammonemia requires a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes. Neurologists, gastroenterologists, emergency medicine physicians, critical care physicians, genetecists, advanced practitioners, nurses, pharmacists, and other health professionals involved in the care of these patients should possess the essential clinical skills and knowledge to diagnose and manage hyperammonemia accurately. Dietitians are key to avoiding triggering amino acid consumption, and pharmacists aid in antibiotic stewardship. Social workers help provide support to patients and their families as needed. Patients with liver failure should be referred to a transplant network when appropriate. This includes expertise in recognizing the varied clinical presentations and understanding the nuances of diagnostic techniques, such as interpreting lab values and clinical findings.

The care of patients with hyperammonemia requires a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes. Neurologists, gastroenterologists, emergency medicine physicians, critical care physicians, genetecists, advanced practitioners, nurses, pharmacists, and other health professionals involved in the care of these patients should possess the essential clinical skills and knowledge to diagnose and manage hyperammonemia accurately. Dietitians are key to avoiding triggering amino acid consumption, and pharmacists aid in antibiotic stewardship. Social workers help provide support to patients and their families as needed. Patients with liver failure should be referred to a transplant network when appropriate. This includes expertise in recognizing the varied clinical presentations and understanding the nuances of diagnostic techniques, such as interpreting lab values and clinical findings. A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize adverse effects. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must know their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of hyperammonemia.